Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 11/20 | 0.45 |
| ▸ | MTOR | P42345 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711693 | 0.90 | CD38 (0.41) | CD38MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL2536578 | 0.88 | CD38 (0.41) | CD38MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL2533306 | 0.88 | PIK3CA (0.42) | CD38MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL2533298 | 0.88 | PIK3CA (0.52) | CD38MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL2531283 | 0.86 | PIK3CA (0.40) | CD38MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL2535022 | 0.82 | KDM4E (0.40) | CD38PIK3CAPIK3CGPIK3CDRAF1 | |
| SCHEMBL2535618 | 0.79 | PIK3CD (0.48) | CD38MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL2532696 | 0.78 | CD38 (0.39) | CD38PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL2528796 | 0.77 | PIK3CA (0.37) | CD38MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL2531943 | 0.77 | TSHR (0.37) | CD38MTORPIK3CAPIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | CD38 1818/4885MTOR 42/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.